Skip to main content

Advertisement

Log in

Effect of Swallow Balloon Therapy with the Combination of Semaglutide Oral Formulation: a Randomised Double-Blind Single-Centre Study

  • Original Contributions
  • Published:
Obesity Surgery Aims and scope Submit manuscript

Abstract

Background

Obesity is a significant public health issue; new therapies and pharmaceutical approaches to weight management are needed.

Objective

This study assesses weight reduction efficacy in the novel swallow balloon procedure and semaglutide, both promising non-surgical and pharmaceutical options, addressing obesity’s critical public health challenge.

Methods

This was a computer-generated, blocked randomisation, double-blind, single-centre study. Fifty-seven participants were assigned to swallow balloon therapy group I (with semaglutide), and 58 were assigned to swallow balloon therapy group II (without semaglutide). All treatment doses were orally administered once daily (3 mg for the 1st month, 7 mg for the 2nd month, and 14 mg for the 3rd and 4th months after the placement of the swallow balloon). All the data were statistically analysed.

Results

The groups were highly well-matched. The %TWL in group I was 7.9%, 12.5%, 15.2%, and 17.6% and in group II was 6.1%, 10.5%, 12.8%, and 13.7% at 1, 2, 3, and 4 months, respectively. The most common adverse events (AEs) were nausea and vomiting, observed within the week. The resolution of T2DM, HTN, and OSA was 64.7% vs 55.5%, 64.3% vs 58.8%, and 72.0 vs 57.8% in groups I vs II, respectively. QoL significantly improved 4 months postoperatively in both groups. No major late complications occurred in either of the groups.

Conclusion

The study supports the efficacy of swallow balloon therapy combined with semaglutide oral formulation in promoting weight loss and improving comorbid conditions. The findings highlight the potential of this combined approach in managing obesity and its associated health issues.

Graphical Abstract

This is a preview of subscription content, log in via an institution to check access.

Access this article

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. De Castro ML, Morales MJ, Del Campo V, et al. Efficacy, safety, and tolerance of two types of intragastric balloons placed in obese subjects: a double-blind comparative study. Obes Surg. 2010;20:1642–6.

    Article  PubMed  Google Scholar 

  2. Machytka E, Chuttani R, Bojkova M, et al. Elipse, a procedureless gastric balloon for weight loss: a proof-of-concept pilot study. Obes Surg. 2016;26:512–6.

    Article  PubMed  Google Scholar 

  3. Raftopoulos I, Giannakou A. The Elipse Balloon, a swallowable gastric balloon for weight loss not requiring sedation, anaesthesia or endoscopy: a pilot study with 12-month outcomes. Surg Obesity Relat Dis. 2017;13(7):1174–82.

    Article  Google Scholar 

  4. Haslam DW, James WP. Obesity. Lancet. 2005;366:1197–209.

    Article  PubMed  Google Scholar 

  5. Drucker DJ. Mechanisms of action and therapeutic application of glucagon-like peptide-1. Cell Metab. 2018;27:740–56.

    Article  CAS  PubMed  Google Scholar 

  6. Wilding JPH, Batterham RL, Calanna S, et al. Once weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384:989–1002.

    Article  CAS  PubMed  Google Scholar 

  7. Chao AM, Tronieri JS, Amaro A, et al. Semaglutide for the treatment of obesity. Trends Cardiovasc Med. Epub ahead of print 21 December 2021. https://doi.org/10.1016/j.tcm.2021.12.008.

  8. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2010;33:S62-69.

    Article  PubMed Central  Google Scholar 

  9. Rosenzweig JL, Ferrannini E, Grundy SM, et al. Primary prevention of cardiovascular disease and type 2 diabetes in patients at metabolic risk: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2008;93(10):3671–89.

    Article  CAS  PubMed  Google Scholar 

  10. Reulen R, Zeegers M, Jenkinson C. The use of the SF-36 questionnaire in adult survivors of childhood cancer: evaluation of data quality, score reliability, and scaling assumptions. Health Qual Life Outcomes. 2006;4:77.

    Article  PubMed  PubMed Central  Google Scholar 

  11. Taft C, Karlsson J, Sullivan M. Do SF-36 summary component scores accurately summarize subscale scores? Qual Life Res. 2001;10(5):395–404.

    Article  CAS  PubMed  Google Scholar 

  12. Bhandari M, Neto MG, Kosta S, et al. Emerging outcomes for treatment of obesity with type 2 diabetes mellitus: novel swallowable balloon process. J Obes Weight Loss Ther. 2022;12:535.

    Google Scholar 

  13. Hughes S, Neumiller JJ. Oral semaglutide. Clin Diabetes. 2020;38(1):109–11.

    Article  PubMed  PubMed Central  Google Scholar 

  14. Machytka E, Chuttani R, Bojkova M, et al. Elipse™, a procedureless gastric balloon for weight loss: a proof-of-concept pilot study. Obes Surg. 2019;26:512–6.

    Article  Google Scholar 

  15. Pratley RE, Crowley MJ, Gislum M, et al. Oral semaglutide reduces HbA1c and body weight in patients with type 2 diabetes regardless of background glucose-lowering medication: PIONEER subgroup analyses. Diabetes Ther. 2021;12:1099–116.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Mohit Bhandari.

Ethics declarations

Conflict of Interest

The authors declare no competing interests.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Mathur, W., Kosta, S., Reddy, M. et al. Effect of Swallow Balloon Therapy with the Combination of Semaglutide Oral Formulation: a Randomised Double-Blind Single-Centre Study. OBES SURG 34, 198–205 (2024). https://doi.org/10.1007/s11695-023-06975-8

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11695-023-06975-8

Keywords

Navigation